Inotiv Inc

Inotiv, Inc. (NASDAQ: NOTV) is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development.

Recent Business and Financial Updates

• Inotiv, Inc. Schedules Fiscal 2025 Second Quarter Financial Results Release and Conference Call: Inotiv, Inc. (NASDAQ: NOTV), a prominent contract research organization based in West Lafayette, Indiana, specializing in nonclinical and analytical drug discovery, development services, and research models, announced on April 23, 2025, that it will release its financial results for the fiscal 2025 second quarter, ending March 31, 2025, after the close of the stock market on Wednesday, May 7, 2025. The Company will also host a conference call on the same day at 4:30 p.m. Eastern Time to review these results with investors and stakeholders.
• Inotiv, Inc. Reports First Quarter Fiscal 2025 Financial Results and Strategic Updates: Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization based in West Lafayette, Indiana, specializing in nonclinical and analytical drug discovery, development services, research models, and related products, announced its financial performance for the first quarter of fiscal 2025, ending December 31, 2024. The Company reported a revenue decline of 11.5% to USD119.9 million compared to USD135.5 million in the same period of the previous year, driven by decreases in both the Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments. To enhance its financial position, Inotiv raised USD27.5 million in net proceeds through the issuance of 6.9 million common shares in December 2024. A conference call to discuss these results is scheduled for today at 4:30 p.m. Eastern Time, accessible via the Company’s investor relations website.
• Management’s Strategic Vision and Financial Enhancements: Robert Leasure Jr., President and Chief Executive Officer, emphasized the Company’s commitment to fostering a more consistent and value-driven organization for its clients, employees, and shareholders. The recent equity offering has bolstered Inotiv’s liquidity, providing the resources to make strategic decisions and pursue sustainable growth. To mitigate revenue volatility, the Company has expanded its non-human primate (NHP) client base and secured pre-sales for 2025, while anticipating steady growth in colony management services. Additionally, Inotiv is optimizing its North American transportation and distribution systems to improve client reliability and efficiency, with the next phase of its RMS site optimization plan expected to yield annual cost savings of USD4.0 to USD5.0 million, reinforcing its dedication to high-quality service delivery.
• Financial Performance and Segment Insights: For the first quarter of fiscal 2025, Inotiv’s consolidated net loss widened to USD27.6 million, or 23.0% of total revenue, from USD15.8 million, or 11.7% of total revenue, in the prior year, reflecting challenges in revenue generation. Adjusted EBITDA decreased to USD2.6 million, or 2.2% of total revenue, from USD9.6 million, or 7.1% of total revenue, in the previous year. Segment performance showed a USD13.7 million, or 15.1%, decline in RMS revenue to USD77.1 million, primarily due to lower NHP pricing, and a USD1.9 million, or 4.2%, drop in DSA revenue to USD42.8 million, driven by reduced discovery service income. The DSA backlog remained stable at USD130.4 million, with a book-to-bill ratio of 1.01x, indicating balanced demand.
• Operational and Capital Resource Developments: Inotiv strengthened its financial structure with a Third Amendment to its agreement with Orient BioResource Center on October 24, 2024, extending the maturity date of the Seller Payable to January 27, 2026. The equity offering, completed in two closings on December 19 and December 30, 2024, enhanced the Company’s cash position to USD38.0 million by December 31, 2024, up from USD21.4 million at the end of September 2024. Cash used in operating activities decreased to USD4.5 million from USD6.5 million in the prior year, while capital expenditure dropped to USD4.5 million from USD5.6 million. Total debt, net of issuance costs, stood at USD396.0 million, with no borrowings on the USD15.0 million revolving credit facility, reflecting prudent financial management.
• Operational Efficiency and Cost Management Initiatives: The increase in operating loss to USD15.5 million in Q1 FY 2025 from USD9.4 million in Q1 FY 2024 was largely attributable to a USD6.3 million decline in RMS operating income, driven by the revenue drop, though partially offset by a USD6.4 million reduction in cost of revenue. This cost decrease was primarily due to lower NHP-related expenses of USD3.9 million, alongside reductions in restructuring, transportation, and costs associated with closed optimization sites. These efforts align with Inotiv’s broader strategy to streamline operations, enhance efficiency, and maintain its reputation as a reliable partner, positioning the Company to navigate current challenges and capitalize on future opportunities.
• Commitment to Client-Centric Growth and Stability: Inotiv remains focused on unifying its operations under a single brand, improving the client experience, and ensuring financial stability through strategic initiatives. The anticipated growth in NHP services and colony management, combined with transportation and distribution optimizations, aims to reduce volatility and enhance service reliability. The projected cost savings from the RMS site optimization plan will further support the Company’s ability to deliver consistent, high-quality solutions. With a strengthened balance sheet and a clear path toward operational excellence, Inotiv is well-positioned to create long-term value for its stakeholders while continuing to meet the evolving needs of its clients in the research and development sector.

Technical Observation (on the daily chart):

The 14-day Relative Strength Index (RSI) is currently at 44.54, currently upward trending, with the expectations of consolidation or upward momentum if the USD 2.30-USD 2.50 resistance is broken on the upside. In addition, the current price is below both the 50-day Simple Moving Averages (SMAs) and 200-day SMA, which may work as medium to long term resistance levels.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given Inotiv, Inc. (NASDAQ: NOTV) at the closing price of USD1.92, as of April 24, 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 24, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.